{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-001228","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.550881+00:00","generated_at":"2026-05-17T20:29:20.112148+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vivani Medical reports positive Phase 1 data for NPM-115 implant and prioritizes semaglutide implant NPM-139","bullets":["Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.","LIBERATE-1 Phase 1 study of NPM-115 (exenatide implant) met primary safety and PK objectives; no serious adverse events.","Preclinical data for NPM-139 (semaglutide implant) showed ~20% weight loss maintained over 231 days from a single implant.","Vivani prioritizes NPM-139 for clinical development, with IND submission planned and clinical start expected in 2026.","Semaglutide products (Ozempic, Wegovy, Rybelsus) generated over $29B in 2024 sales, supporting prioritization."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-001228","json":"https://secwatch.observer/filing/0001753926-25-001228.json","markdown":"https://secwatch.observer/filing/0001753926-25-001228.md","text":"https://secwatch.observer/filing/0001753926-25-001228.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625001228/0001753926-25-001228-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392625001228/vani-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-17T20:29:20.112148+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}